Last update 04 Nov 2024

Cyclopentolate Hydrochloride

Last update 04 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(±)-cyclopentolate, 1-hydroxy-α-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester, 2-(dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate

+ [16]

Target

mAChRs

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Nervous System DiseasesEye DiseasesOther Diseases

Active Indication

Eye DiseasesCycloplegiaIritis+ [1]

Inactive Indication-

Originator Organization

Santen Pharmaceutical Co., Ltd.

Active Organization

Santen Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (23 Sep 1971),

Eye Diseases

Regulation-

Structure

Molecular FormulaC17H26ClNO3

InChIKeyRHKZVMUBMXGOLL-UHFFFAOYSA-N

CAS Registry5870-29-1

Clinical Trials associated with Cyclopentolate Hydrochloride

ChiCTR2400084750 / SuspendedEarly Phase 1IIT

Comparison of the effects of pupil dilation and ciliary muscle paralysis of 1% tropicamide, 0.5% tropicamide and 1% cyclopentolate

Start Date31 May 2024

Sponsor / Collaborator-

NCT06077682 / RecruitingPhase 4IIT

Tropicamide Versus Cyclopentolate for Cycloplegic Refraction in Pediatric Patients With Esotropia: A Randomized Clinical Trial

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations with esotropia. This will be a prospective double-blinded randomized clinical trial (RCT), multi-center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

Start Date01 Sep 2023

Sponsor / Collaborator

The Islamic Hospital

[+2]

NCT05442801 / CompletedPhase 4IIT

Tropicamide Versus Cyclopentolate Objective Refraction in Pediatric Population

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations. This will be a prospective double-blinded randomized clinical trial (RCT), multi center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

Start Date01 Mar 2022

Sponsor / Collaborator

The Islamic Hospital

100 Clinical Results associated with Cyclopentolate Hydrochloride

100 Translational Medicine associated with Cyclopentolate Hydrochloride

100 Patents (Medical) associated with Cyclopentolate Hydrochloride

577

Literatures (Medical) associated with Cyclopentolate Hydrochloride

01 Dec 2024·AMERICAN JOURNAL OF OPHTHALMOLOGY

Intracameral Anaesthetic Mydriatic Versus Topical Mydriasis in Pediatric Cataract Surgery: A Randomized Control Study

Article

Author: Sen, Indu ; Kumari, Kiran ; Gupta, Kajree ; Kaur, Savleen ; Sukhija, Jaspreet

PURPOSE:

To compare pupil dynamics after using premixed intracameral anesthetic mydriatic combination (ICAM) of phenylephrine (0.31%), tropicamide (0.02%), and lidocaine (1%) versus topical mydriatic (TM) drops consisting of tropicamide 0.8%, phenylephrine 5%, and cyclopentolate 0.5% in pediatric cataract surgery.

DESIGN:

Randomized, masked, fellow eye-controlled trial.

SETTING:

Tertiary eye care facility.

STUDY POPULATION:

Children ≤12 years of age with bilateral cataracts planned for surgery. One eye was randomized to receive ICAM and the other eye (control) TM drops.

INTERVENTION:

Commercially available ICAM that was injected at the beginning of surgery or TM 3 times at an interval of 30 minutes, 1 hour before the scheduled time of surgery. The other treatment was administered for the second eye cataract surgery.

MAIN OUTCOME MEASURE:

Pupil dynamics at various points of surgery were studied by a masked observer.

RESULTS:

Sixty-three patients (126 eyes) were randomized to receive ICAM in 1 eye (group 1) or TM drops (group 2). The mean age of the children in the study was 15.7 ± 24.3 months (range 3 months to 5 years). Adequate mydriasis with a single injection was achieved in 93.5% of patients in group 1 and 88.8% of patients in group 2 without additional pharmacotherapy or intervention. The mean pupillary diameter increased from 1.78 mm to 5.1 mm after injection of 1 unit of ICAM and from 1.75 mm to 6.06 mm with TM drops (P < .0001). The maximum pupillary dilation achieved was 6.06 ± 1.17 mm in group 1 and 6.75 ± 1.07 mm in group 2 (P = .004). The average change in pupillary size from injection of drug until the end of surgery was positive in group 1 (0.75 ± 0.98 mm) and negative in group 2 (-0.3348 ± 2.57 mm), ie, there was a relative miosis in group 2 toward the end of surgery (P = .001).

CONCLUSIONS:

Topical drugs achieved a larger maximum pupil size compared with ICAM. However, ICAM provided adequate and stable mydriasis without the need for augmentation compared with topical drops in children undergoing cataract surgery.

01 Oct 2024·Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Effects of cycloplegia on crystalline lens morphology and location in acute acquired concomitant esotropia

Article

Author: Liu, Jiawen ; Chen, Jiayu ; Chen, Weibin ; Dai, Wei ; Hao, Jie ; Fu, Jing

PURPOSE:

The study aims to compare morphology and location of crystalline lens between acute acquired concomitant esotropia (AACE) patients and control subjects, both before and after cycloplegia.

METHODS:

This is a prospective and observational clinical study. Morphological and locational parameters of the crystalline lens in 53 AACE patients and 32 control subjects were assessed before and after cycloplegia using CASIA2 system, which represents the latest swept-source anterior segment optical coherence tomography. Cycloplegic refraction was recorded by administering 1% atropine in patients younger than 12 years and 1% cyclopentolate in those > 12 years old. Morphological parameters included anterior radius of curvature (ARC), posterior radius of curvature (PRC), lens thickness (LTH), and equivalent diameter of lens (LED). Locational parameters comprised lens decentration (LD) and lens tilt (LT). Comparison of these parameters before and after cycloplegia were conducted between AACE and controls. Additionally, the study analyzed and compared the changes in these parameter post-cycloplegia.

RESULTS:

Our findings suggest no significant difference in morphological parameters including ARC, PRC, LTH and LED between AACE patients and controls before or after cycloplegia. However, 2D-modeling data in the 0° meridian revealed that variation post-cycloplegia of LD (lens shift) in right eyes was different in AACE patients, measuring - 0.03(0.08) [median(interquartile range)] which was significantly distinct from the control group, exhibiting a measurement of 0.01(0.06) (z = - 2.373, p = 0.018). In left eyes, a similar trend was observed with lens shift in the 0° meridian being 0.02(0.06) in AACE, significantly differing from control group's measurement of - 0.02(0.08) (z = - 2.809, p = 0.005). Further, correlation analysis revealed that larger temporal shift of lens was associated with greater changes in ARC (r = 0.294, p = 0.006) and LTH (r = - 0.230, p = 0.031).

CONCLUSIONS:

The morphological features of the crystalline lens were similar in AACE patients and controls; however, the change of lens location by cycloplegia was observed only in AACE patients, suggesting an association with excessive accommodation.

02 Jul 2024·Cutaneous and Ocular Toxicology

The effect of three different mydriatic eye drops on retinal vessel diameters

Article

Author: Sayin, Osman ; Altinkaynak, Hasan

PURPOSE:

To investigate the effects of topically applied 1% tropicamide, 2.5% phenylephrine and 1% cyclopentolate on retinal vessel calliper (VC) using optical coherence tomography (OCT).

METHODS:

Patients who came to the ophthalmology clinic for routine examination and whose OCT films were taken before dilatation and after 30 min of last dilatation drop were included in the study. 90 ophthalmologically healthy subjects were divided into 3 groups of 30 subject each according to the application of the drops as follows: Tropicamide group (Group 1), Phenylephrine group (Group 2), Cyclopentolate group (Group 3). The right eyes of the subjects were dilated with drops and the left eyes were taken as the control group. VC of retinal artery and vein passing through an area one-half to one-disc diameter from the optic disc margin were measured from OCT films. The mean of the sum of superior retinal artery (SRA) and inferior retinal artery (IRA) VC and the mean of the sum of superior retinal vein (SRV) and inferior retinal vein (IRV) VC before and after the drop were compared.

RESULTS:

There was no statistically significant change in the mean sum of SRA and IRA VC and the mean sum of SRV and IRV VC before and after dilatation drops in all three groups.

CONCLUSION:

Dilatation drops have no statistically significant effect on retinal artery and vein VC.

News (Medical) associated with Cyclopentolate Hydrochloride

12 Aug 2024

·www.prnewswire.com

OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics (" OcuMension") announced an agreement with Alcon Inc. (" Alcon", and collectively with OcuMension, the " Parties") where OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops, including several commercially available products and one development-stage product. The scope of the agreement will also cover areas of R&D, manufacturing and commercialization in China. In connection with the transfer of these rights, OcuMension will issue 139,161,120 shares to Alcon, accounting for 16.71% of the total share capital (post-issuance). Consequently, Alcon becomes one of the largest shareholders of OcuMension. Under the terms of the arrangement, each company has granted the other company a right of first negotiation over future products. OcuMension, as a leading Chinese ophthalmic pharmaceutical platform company, focuses on integrating comprehensive capabilities across the entire lifecycle of ophthalmic drug development—from research and development to commercialization. OcuMension possesses a portfolio of 25 pharmaceutical assets. Alcon, the global leader in eye care, offers a broad portfolio of products to enhance sight and improve lives for patients in more than 140 countries. Under this arrangement, OcuMension will acquire outright, Tears Natural® Forte, Bion Tears, Alcaine®, Fluorescite, and Cyclogyl, in the Chinese market and the commercialization rights in China to Systane® Ultra and AR-15512, a novel topical drug candidate for dry eye. Under the terms of this agreement, OcuMension will manufacture those products acquired outright for China after a transition period. OcuMension will also develop, manufacture and commercialize AR-15512 in China. The addition of these seven mature products and AR-15512 to OcuMension's portfolio is expected to further enhance OcuMension's leadership in the ophthalmology field in the China market. Through the acquisition of these products, OcuMension expects to be capable of providing more comprehensive and advanced treatment solutions, further meeting patient needs and expanding market share. The Parties expect that the framework of this agreement will allow both Parties to further promote technological advancements and innovations in the field of ophthalmology. Ophthalmic diseases are internationally recognized as one of the highly focused medical sub-sectors, with innovative treatment solutions for ophthalmology still awaiting development. Based on this, OcuMension will continue to focus on bringing safer, more efficient, and cutting-edge treatment solutions to global ophthalmic patients, meeting the growing medical needs of patients. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, Alcon offers the broadest portfolio of products to enhance sight and improve people's lives. Alcon's Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Alcon's more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at . About OcuMension OcuMension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. OcuMension's vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since its inception, OcuMension has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. OcuMension believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors. Advisors Morrison Foerster acted as legal advisor to OcuMension in this transaction. Lazard acted as financial advisor to Alcon and Gibson Dunn as its legal advisor. SOURCE OcuMension

AcquisitionLicense out/in

100 Deals associated with Cyclopentolate Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01002	Cyclopentolate Hydrochloride	S01FA04	DB00979

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Diseases	JP	Santen Pharmaceutical Co., Ltd.	23 Sep 1971
Cycloplegia	US	-	-
Cycloplegia	-	-	-
Iritis	-	-	-
Mydriasis	US	-	-
Mydriasis	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02909140 (CTgov)	Not Applicable	Cataract	3	Topical phenylephrine 2.5%+Topical cyclopentolate 1%+Intracameral Lidocaine 1% (Topical Mydriasis)	rlhtwywmxb(ltvdgmnpsg) = tgnclxiqsg zamhwzlmbz (ntknncbrds, pgwbzycgee - roahwrfbvr) View more	-	10 Sep 2019
				Intracameral Lidocaine 1% (Intracameral Mydriasis)	iphuwndyre(dpvvftryjh) = xmvmmsedzn ssmmzfifra (bdcpkxlrgr, zigjtwxtmh - qxpansmtos) View more
Pubmed \| Curr Eye Res	Not Applicable	Retinopathy of Prematurity	25	Cyclopentolate	hselsxrpgg(gxmzpghgas) = Preterm infants undergoing Retinopathy of Prematurity Eye Exams (ROPEE) may experience adverse events, possibly from systemic absorption of cyclopentolate. jfefisfwlp (sdtwvzvloo ) View more	-	01 Dec 2016
				Cyclopentolate
ARVO2015	Not Applicable	-	8	Cyclopentolate 1%	oyajbmlcrj(epmwafugeu) = nnblcvlfbw hcsdzijqvc (tjmmccidkq ) View more	-	01 Jun 2015
Pubmed \| Eur J Ophthalmol	Not Applicable	Retinopathy of Prematurity	1,246	Phenylephrine 2.5% with Cyclopentolate 0.5%	gayzikickf(vmlwiifwwn) = wbjfldhvxe nypqwfsbad (pnyjbehnug )	-	01 May 2015
ARVO2013	Not Applicable	Myopia	28	cyclopentolate	uqiyigspci(jlpypgkcqj) = cvvnqommld crqhhgofjz (vsygzfbkpv ) View more	-	01 Jun 2013
Multi-Ethnic Pediatric Eye Disease Study (ARVO2008)	Not Applicable	Refractive Errors	24	Cyclopentolate	pzwtmahggs(sxqypwzxob) = uqfumqghbn lbvrhsnnua (jhmgygesmn, 0.85) View more	Positive	01 May 2008
				Atropine	pzwtmahggs(sxqypwzxob) = jpoheiwgbp lbvrhsnnua (jhmgygesmn, 0.85)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis